DSGN
Design Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.68Close
$645.1MMarket cap
$6.24 – $15.9452-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Far from its high 33% below its 52-week high
- Distribution down-day volume 1.7× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
up 4.3%
price change
1mo
down 15.0%
price change
12-month return
up 64%
market up 11% ·
its own up 54%
F-score
—
— Not assessed
Altman Z
26.37
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
down 12.7%
EBIT / enterprise value
Cheaper than
23%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 31%
return on equity
Free cash margin
—
-$54.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.2%
$0.66 a day · 2×ATR $9.36
RS
50 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.4×
vs 50-day average
Up/down volume
0.59
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 6.4% over the year, from 57m to 60m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 3, 2026
Results reaction
Aug 3, 2026+5% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $226,000 | — | — | — | $0 | $0 |
| Operating income | -$8.3M | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M |
| Net income | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Net margin | -3664% | — | — | — | — | — |
| Earnings per share | — | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 |
| Free cash flow | -$8.7M | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M |
| Free cash margin | -3869% | — | — | — | — | — |
| Cash | $2.4M | $298.6M | $26.5M | $21.2M | $22.6M | $16.9M |
| Shareholders' equity | -$11.3M | $382.1M | $327.3M | $277.7M | $242.1M | $212.5M |
| Shares outstanding | 15.96m | 55.44m | 55.90m | 56.47m | 56.75m | 60.40m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Mar 9, 2026 | Annual ↗ | Dec 31, 2025 | 68d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Mar 10, 2025 | Annual ↗ | Dec 31, 2024 | 69d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 3, 2026 | Results ↗ |
| Jun 11, 2026 | Shareholder vote ↗ |
| May 18, 2026 | Other events ↗ |
| Apr 28, 2026 | Results · Regulation FD ↗ |
| Apr 1, 2026 | Director or officer change ↗ |
| Mar 9, 2026 | Results ↗ |
| Jan 30, 2026 | Director or officer change ↗ |
| Nov 5, 2025 | Results ↗ |
| Sep 10, 2025 | Director or officer change ↗ |
| Aug 7, 2025 | Results · Regulation FD ↗ |
| Jun 12, 2025 | Shareholder vote ↗ |
| May 7, 2025 | Results ↗ |